Next Article in Journal
Text Sentiment Classification Based on BERT Embedding and Sliced Multi-Head Self-Attention Bi-GRU
Next Article in Special Issue
Healthcare Monitoring Using Low-Cost Sensors to Supplement and Replace Human Sensation: Does It Have Potential to Increase Independent Living and Prevent Disease?
Previous Article in Journal
Illumination Temporal Fluctuation Suppression for Single-Pixel Imaging
Previous Article in Special Issue
An Electrochemical Sensor for Sulfadiazine Determination Based on a Copper Nanoparticles/Molecularly Imprinted Overoxidized Polypyrrole Composite
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Sensors
Volume 23
Issue 3
10.3390/s23031482
sensors-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Biomarkers and Corresponding Biosensors for Childhood Cancer Diagnostics

by
Azadeh Gharehzadehshirazi
1,
Mashaalah Zarejousheghani
2,
Sedigheh Falahi
1,
Yvonne Joseph
1,2 and
Parvaneh Rahimi
1,2,*
1
Institute of Electronic and Sensor Materials, Faculty of Materials Science and Materials Technology, Technische Universität Bergakademie Freiberg, 09599 Freiberg, Germany
2
Freiberg Center for Water Research—ZeWaF, Technische Universität Bergakademie Freiberg, 09599 Freiberg, Germany
*
Author to whom correspondence should be addressed.
Sensors 2023, 23(3), 1482; https://doi.org/10.3390/s23031482
Submission received: 29 December 2022 / Revised: 26 January 2023 / Accepted: 26 January 2023 / Published: 28 January 2023
(This article belongs to the Special Issue Feature Papers in Biosensors Section 2022)
Browse Figures
Review Reports Versions Notes

Abstract

:
Although tremendous progress has been made in treating childhood cancer, it is still one of the leading causes of death in children worldwide. Because cancer symptoms overlap with those of other diseases, it is difficult to predict a tumor early enough, which causes cancers in children to be more aggressive and progress more rapidly than in adults. Therefore, early and accurate detection methods are urgently needed to effectively treat children with cancer therapy. Identification and detection of cancer biomarkers serve as non-invasive tools for early cancer screening, prevention, and treatment. Biosensors have emerged as a potential technology for rapid, sensitive, and cost-effective biomarker detection and monitoring. In this review, we provide an overview of important biomarkers for several common childhood cancers. Accordingly, we have enumerated the developed biosensors for early detection of pediatric cancer or related biomarkers. This review offers a restructured platform for ongoing research in pediatric cancer diagnostics that can contribute to the development of rapid biosensing techniques for early-stage diagnosis, monitoring, and treatment of children with cancer and reduce the mortality rate.

1. Introduction

A cancer diagnosis is always distressing, particularly when the patient is a child, since having cancer causes many changes in a child ‘s life. Cancer is a major cause of death in children around the world. It is estimated that each year, around 400,000 children and adolescents from 0–19 years old are diagnosed with cancer worldwide [1]. Cancers are caused by a change in one or more genes in single cells, which then grow into a tumor. Contrary to cancers in adults, the majority of cases in children are idiopathic. However, about 10% of cases are due to germline mutation, which is almost always not inherited, i.e., family history cannot predict the presence of cancers in these patients [2]. A number of factors can impact the outcome of a tumor, including the biological characteristics and pathway of a neoplasm’s carcinogenesis, modes of presentation, time to diagnosis, and treatment options. Sometimes, the initial symptoms may be confused with other illnesses’ conditions, particularly in pediatrics cases, which makes it difficult to suspect a tumor [1,3]. The chance of a child surviving a cancer highly depends on the region where the child lives, as most cases of cancers in children need advanced technologies and specialists for diagnosis, effective therapies, and support, which are usually unaffordable and unavailable in low- and middle-income countries (LMICs) [4]. Generally, in high-income countries, more than 80% of children diagnosed with cancer are cured, whereas the cure rate in LMICs is less than 30% [3,4].
The types of cancers in children are entirely different from the ones affecting adults. In general, the most common children’s cancer types by proportion of overall child cancer rates are leukemias, followed by central nervous system (CNS) tumors and lymphomas. However, the type of cancer can vary to some extent by age [5]. Screening and diagnostic tests for the detection of cancers have always been challenging in both adults and children. Traditional tumor biomarkers that are found in blood, urine, cerebrospinal fluid (CSF), or even body tissues and are raised in connection with cancer have been used in oncology for a long time. Furthermore, different imaging modalities such as X-ray (plain film and computed tomography [CT]), ultrasound (US), magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), positron emission tomography (PET), and optical imaging have been available in areas of cancer detection and follow-up. However, these methods are expensive, require highly qualified personnel, and may not be accurate, sensitive, or specific enough to detect a tumor. On the other hand, overdiagnosis by existing methods is still a major concern, since there is a need to avoid exposing a patient to invasive treatments. Additionally, biopsy as a definite diagnostic test is an invasive technique that sometimes needs short admission. Furthermore, the earlier and more precise diagnosis of cancer maintains a higher chance of cure. In this regard, rapid, sensitive, and specific detection of cancer biomarkers using biosensors has great clinical significance for the diagnosis of various cancers [6,7].

2. Potential Biomarkers for Childhood Cancers

Advancements in biochemistry and analytical instruments have played an important role in the identification of appropriate biomarkers and the development of corresponding biosensors, leading to significant improvements in treatment of patients in all age groups [8]. In accordance with the National Cancer Institute, a biomarker is “a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease “. Cancer biomarkers are biological factors that are identified to develop decisive, cost-effective, and non-invasive agents for early detection and monitoring of cancers. These biomarkers consist of a broad range of molecules, such as DNA, RNA, enzymes, metabolites, transcription factors, and cell surface receptors, that can be measured objectively by various techniques [9,10].
Due to the wide range of pediatric cancers and constant advances in molecular diagnostic techniques, in this review, we have focused on the most common cancer group in children.

2.1. Leukemias

Leukemias, which are defined as abnormal proliferations of immature white blood cells (WBC), are kinds of hematologic malignancies that do not form solid neoplasms. Leukemias are the most common type of cancer in children, accounting for 28% of all cancers in children [11,12]. Leukemias are originated either from myeloid or lymphoid lineages, and they are categorized naturally as acute (non-mature cells) and chronic (more mature cells) [13]. More than 80% of leukemias in children are acute lymphoblastic leukemias (ALL) and the rest are mostly acute myeloid leukemias (AML). Chronic leukemias are very rare in children; however, most cases are chronic myelogenous leukemia (CML) [14]. Symptoms of anemia, thrombocytopenia, neutropenia, and persistent bone pain are typical leukemia presentations due to clonal proliferation of blasts in the bone marrow. Fever, hepatosplenomegaly, and CNS involvement are other manifestations of children with leukemia. Many of these symptoms overlap with other common childhood illnesses and make the diagnosis of leukemia complicated. In addition, acute leukemias can grow rapidly, so they need to be diagnosed and treated as soon as possible [15].
Several biomarkers have been identified and reviewed for screening, diagnosis, prognosis, and treatment monitoring in childhood leukemia. Among them, a cluster of differentiation (CD) markers, a series of membrane proteins, are widely used for classifying WBCs and also diagnosing blast cells from normal WBCs. CD19, CD20, CD22, CD 24, and CD79a are important markers for diagnosis and differentiating Burkitt type ALL (B-ALL) from other types of leukemias. In pro-B ALL (an unfavorable subset of ALL), lymphoblasts are positive for CD19, CD22, CD34, cytoplasmic (cy) CD79a, and TdT. Lymphoblasts in pre-B ALL are positive for CD10, CD19, CD22, CD34, TdT, cy CD79a, and Cy mµ. Thymic ALL (T-ALL) are positive for CD1a, cy CD3, CD5, CD7 and TdT [16,17]. Furthermore, there are specific genetic abnormalities of leukemic cells that play important roles as biomarkers in prognosis and therapy of leukemias. A number of these chromosomal abnormalities that act as potential markers include t(9;22), t(12;21), t(8;21), t(15;17), BCR-ABL, TEL-AML1, AML1-ETO, and PML-RARA [18,19]. Proteomic biomarkers that are other potentially interesting biomarkers for early diagnosis of ALL were reported by Shi et al. [20]. They identified platelet factor 4 (PF4), a kind of connective-tissue-activating peptide (CTAP III), and fragments of the complement component 3a (C3a) as proteomic biomarkers in the sera of ALL patients [20]. In addition, several miRNAs have been identified in patients with ALL, which have diagnostic and prognostic values. For instance, miRNA-328 and miRNA-200 are suggested as two novel biomarkers for diagnosis and prognosis, as well as miRNA-324-3p, miRNA-508-5p and miRNA-128 as potential diagnostic biomarkers of childhood ALL. [21,22,23]. Among other biomarkers related to leukemia, human leukemic lymphoblasts (CCRF-CEM) are cellular biomarkers that can be detected in the peripheral blood of children with acute leukemia [24].

2.2. CNS Tumors

Brain and spinal tumors are the second-most-common group of cancers and the leading cause of morbidity and mortality in children, representing about 25% of childhood cancers [25]. CNS tumors are normally classified on the basis of histologic features of the tumor and its probable site of origin in the brain. Nonetheless, the most common types of brain and spinal cord tumors in children are medulloblastoma (MB) and glioma [26]. Brain tumors in children are mostly infratentorial and cause acute manifestations related to a blockage in the flow of the CSF (headache, nausea, vomiting, irritability, abnormal breathing, etc.). However, in the long term, they may present with macrocephaly, delayed psychomotor development, loss of appetite, etc. [27]. Neuroimaging is the primary diagnostic technique for any kind of brain tumor; nonetheless, recently identified potential diagnostic, prognostic, and predictive biomarkers have become key tools for the management of these tumors [28,29]. CSF is considered as the most productive source for biomarkers in childhood CNS tumors because of its close vicinity to the tumor mass [30]. In a study, six proteins in CSF samples of patients with CNS tumors were identified as prospective biomarkers for metastasis spread, including type 1 collagen, insulin-like growth factor binding protein 4, procollagen C-endopeptidase enhancer 1, glial-cell-line-derived neurotrophic factor receptor α2, inter-alpha-trypsin inhibitor heavy chain 4, and neural proliferation and differentiation control protein-1 [31]. Recently, Bruschi et al. introduced six promising biomarkers from CSF of children with different brain tumors. Among these biomarkers, TATA-binding protein-associated factor 15 and S100 protein B were able to differentiate between control and tumor cases [32]. TMSB4X, a cytoskeletal protein inhibiting actin polymerization involved in tumorigenesis, and CD109, a glycosylphosphatidylinositol-anchored cell surface antigen expressed by T-cells and endothelial cells, are biomarkers found in CSF of patients with pilocytic astrocytoma (PA), a low-grade cerebellum glioma, that can discriminate PA from all other brain tumors [33,34,35]. Another instance is tripartite motif-containing protein 33 (TRIM33), which is a transcriptional corepressor suppressor of brain tumor development that can distinguish PA from the more aggressive diffuse gliomas [36,37]. Recently, Bookland et al. [38] introduced miRNA-21, miRNA-15b, miRNA-23a, and miRNA-146b as four miRNAs that can predict the presence, tumor nodule size, and response to therapy of PA with a high sensitivity and specificity. Heat shock proteins (HSPs), which belong to a superfamily of chaperones, along with 14.3.3 as an inhibitor of apoptosis are overexpressed in MB and can discriminate between MB and all other brain tumors [39,40,41]. Circ NFIX RNA is another biomarker that is considerably upregulated in glioma cancer cells and has attracted scientists’ attention, since Circ NFIX could regulate signaling pathways leading to human glioma cancer progression [42]. Among the biomarkers, glioblastoma-derived specific exosomes, which release directly from tumor cells in brain and cross the blood–brain barrier, hold great potential for early diagnosis of glioblastoma (GBM, a type of glioma) [43].

2.3. Neuroblastoma

Neuroblastoma (NB) is the most common cancer diagnosed in the first year of infancy [44]. This embryonal malignancy is derived from primordial neuronal crest cells and is mostly located in adrenal medulla and along the sympathetic nervous system [45]. The NB’s symptoms depend on the anatomic location of the tumor and the stages of the disease. Most patients have presentations related to a mass in the belly, such as abdominal distention, constipation, and high blood pressure. In cases arising from paravertebral sympathetic ganglia, the spinal cord is usually invaded and patients may have manifestations such as pain, motor sensory deficit, or Horner syndrome (drooping eyelid, small pupil, and lack of sweating on one side of face) [46,47,48,49]. There are multiple imaging techniques and tests for diagnosis of neuroblastoma. Ultrasonography is usually the first modality in a child with a suspicious abdominal mass, followed by CT or MRI for further evaluation of the tumor extension and stage [50]. Furthermore, nuclear medicine imaging techniques such as meta-iodobenzylguanidine (MIBG) and fluorodeoxyglucose (FDG) imaging are often used to define tumor status and detect occult disease and probable metastasis [51]. Along with imaging, there are several biomarkers in neuroblastoma that are valuable in the process of tumor accessing. They can be divided into two main groups: 1) Amplification of genetic and molecular biomarkers such as MYCN (a protein-coding gene), ALK (anaplastic lymphoma receptor tyrosine kinase gene) amplification and mutations, chromosomal segments loss or gain, and dysregulated proteins such as PIM kinase, Far-Upstream Element-Binding Protein 1 (FUBP1), Ubiquitin C-Terminal Hydrolase L1 (UCHL1), and Tropomodulin1 (TMOD). 2) Circulating biomarkers in serum such as neuron-specific enolase (NSE), circulating tumor cells (CTCs), and miRNAs (such as overexpression of miR-124-3p, miR-9-3p, miR218-5p, miR490-5p, or miR1538), as well as circulating biomarkers in urine, including catecholamines and their derivatives such as 3-Methoxytyramine (3-MT), homovanillic acid (HVA), vanillylmandelic acid (VMA), normetanephrine (NMN), and vanillactic acid (VLA) [52,53,54].

2.4. Wilms Tumor

Wilms tumor (WT) or nephroblastoma is the most common kind of primary kidney tumor and the third-most-common solid tumor in children, accounting for about 5% of all childhood cancers [55,56]. Wilms tumor may be associated with different congenital anomalies and syndromes such as WAGR syndrome (a rare genetic disorder and acronym for Wilms tumor, Aniridia, Genitourinary anomalies, and mental Retardation), Beckwith–Wiedemann syndrome (macrosomia, macroglossia, abdominal wall defects, Wilms tumor, hypoglycemia in the newborn period, and unusual ear creases or pits) and Denys–Drash syndrome (abnormal kidney function, disorders of sexual development in affected males and Wilms tumor) [57,58]. The most usual feature of WT is a large and painless abdominal mass in a clinically healthy child [59]. However, about 20% of patients with WT also show symptoms such as abdominal pain, constipation, urinary tract infections, blood in the urine, high blood pressure, fever, and weight loss [60,61].
A child with suspected WT is typically examined with imaging techniques in the first stage. Ultrasound is normally the first choice, which is then followed by further imaging such as CT or MRI in order to define the stage of the tumor [62,63].
There are a number of biomarkers that have been most identified for their role in WT characteristics and histology. Among them, loss of heterozygosity (LOH) for both chromosomes 1p and 16q, which is closely associated with tumor recurrence; mutation in B7-H1 (programmed death-ligand 1 = PD-L1) as a biomarker of the immune system, which is related to an increased risk of tumor recurrence; and mutation in P53, which is involved in an increased risk of recurrence, are promising biomarkers in identifying WT [64,65,66]. Furthermore, Ludwig et al. [67] have recently identified miR-100-5p, miR-130b-3p, and miR-143-3p with diagnostic potentials for differentiation of WT from controls. They reported that among three recognized miRNAs, higher expression of miRs-100-5p and -130b-3p in the serum of patients with WT has the greatest potential for tumor diagnosis regardless of its subtype.

2.5. Lymphomas

Lymphomas originate in transformed cells of the lymphatic system (germinal-center B cells). There are two major groups of lymphomas, Hodgkin lymphomas (HL) and non-Hodgkin Lymphomas (NHL), and both types occur in children. However, HL is the most common lymphoma in children, accounting for approximately 6% of all children’s malignancies, and is most frequent in adolescents [68]. Lymphomas typically affect the whole body. Most patients with lymphoma present with non-tender lymph node swelling that may be followed by constitutional symptoms (fever, fatigue, loss of appetite, sweating, weight loss, or not gaining weight) [69]. Imaging plays a crucial role in the diagnosis, staging, and follow-up of patients with lymphoma. CT, MRI, and PET are conventional imaging modalities used in patients with lymphomas for further evaluations [70]. Most lymphomas are potentially curable when they are diagnosed and treated with a standard care method. However, recognizing different lymphoma subtypes can be challenging due to the overlapping features of various lymphoma groups. Thus, the identification of clinically valuable biomarkers may facilitate the diagnosis and classification of lymphoma, which in turn should lead to better stratification of patients and more efficient and less toxic treatment of children with lymphoma. In this regard, serum CD163 and serum thymus and activation-regulated chemokine (TARC) are proposed as striking biomarkers reflecting therapy response in patients with HL [71]. CCL17/TARC is another biomarker with the potential to facilitate primary care triage and chemotherapy monitoring strategies for classic Hodgkin lymphoma (cHL) [72]. Determining the levels of a combination of biomarkers such as Nuclear Factor Kappa B (NF-κB) and CD30 in pediatric HL patients would support gaining insight into disease progression during tumor treatment [56]. Additionally, four biological and inflammatory markers (stage IV, high platelet count, ferritin, and eosinophils) were investigated by Farruggia et al. to classify pediatric patients with HL into subtypes with various outcomes [73]. More recently, Yu et al. [74] identified S100 calcium-binding protein A8 (S100A8) and leucine-rich alpha-2-glycoprotein 1 (LRG1) as promising biomarkers for the diagnosis of pediatric NHL.

3. Biosensors for Detection of Biomarkers

Cancer biomarkers are commonly detected by conventional techniques, including enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), Western blotting, immunofluorescence, flow cytometry, and liquid chromatography–mass spectrometry [75,76,77,78,79]. Nevertheless, these assays are complex, time-consuming, require complicated and expensive instrumentation, and sometimes fail to detect a low concentration of biomarkers in the early stages of cancer. Therefore, the development of a reliable, rapid, and sensitive method for biomarker detection, especially in the early stages of cancer, is essential. In this regard, biosensors have shown attractive features compared to the techniques mentioned earlier and have improved health and quality of life. On the other hand, biosensors are promising candidates for the specific and simultaneous detection of biomarkers and the study of their associated reactions, because their components can be easily modified and improved.
A biosensor is an integrated receptor–transducer device capable of transforming a biological reaction into a measurable signal, which can be further amplified and analyzed (Figure 1) [80,81]. The biorecognition element has the most important function in the biosensor, as it defines the selectivity and sensitivity of the designed biosensor by specific binding to a target analyte. Therefore, selecting a suitable bioreceptor is the first step to improving the biosensors’ design and development [82,83]. At this point, various types of biosensors have been developed for the determination of cancer biomarkers. Many researchers have enhanced the sensitivity of biosensors by integrating nanomaterials into biosensing assays [84,85]. Novel chemical, physical, optical, and electrical properties of different nanomaterials and their large specific surface areas can significantly improve the ability of biosensors to detect biomarkers. In addition, it is proved that the detection of multiple biomarkers can remarkably advance the specificity of a biosensor for the diagnosis of early-stage cancer [85,86].

4. Developed Biosensors for Childhood Cancers in Clinical Practice

To date, numerous cancer biomarkers have been identified for various cancers in children and adults. Although a variety of biosensors have been developed for biomarker detection, only a limited number of them have been designed for childhood cancers. Here, the developed biosensors for biomarker detection related to childhood cancers are reviewed

4.1. Electrochemical Biosensors

Among the developed biosensing technologies for cancer biomarker detection, electrochemical biosensors have gained much attention due to their low cost, ease of use, suitability for miniaturization, fast response time, and high sensitivity with low detection limit. In particular, electrochemical nano-biosensors using various nanomaterials have been recently used for ultra-sensitive detection of biomarkers [87].
Mazloum Ardakani et al. [88] developed a set of disposable electrochemical nano-biosensors for early detection of acute lymphoblastic leukemia. Their biosensor package included a DNA sensor, an aptasensor that can detect BCR-ABL1 as a mutant gene, and carcinoembryonic antigen (CEA) as a cancer biomarker. To improve the sensitivity of their biosensors, they used a nanocomposite of carbon quantum dots and gold nanoparticles (Au NPs) for preparing both DNA and aptamer biosensors. With the proposed nano-biosensor package, they could detect BCR-ABL1 and CEA in a wide linear range with the detection limits of 1.5 and 0.95 pM, respectively. According to their research, a negative test result of DNA sensor was related to a person who did not have ALL. In contrast, a positive DNA test suggested that the patient had a mutant gene and was at risk of ALL. The aptamer test was performed to verify the positivity in case of a positive DNA test. A positive aptasensor test illustrated that the patient definitely had ALL. On the contrary, a negative aptasensor test would mean that the person had no ALL but was at risk of ALL because of having the mutant gene responsible for ALL.
Avelino et al. [89] developed a simple, rapid, and highly sensitive electrochemical DNA biosensor to diagnose BCR/ABL oncogene for both ALL and CML at attomolar concentrations. They used a composition of Au-NPs and polyaniline, an organic–inorganic hybrid material, with synergistic properties and robust biosensitive platforms, to attach DNA probes to the gold electrode. By applying complementary DNA (cDNA) samples from patients to the biosensor surface and hybridizing with immobilized DNA probes, the concentration of the BCR/ABL fusion gene could be determined at the lowest concentration compared with the other reported values.
Dinani et al. [23] fabricated an aptasensor based on Au NPs/Fe3O4/reduced graphene oxide (rGO) for the determination of miRNA-128 concentration as a diagnostic biomarker for ALL. They decorated the rGO films with Fe3O4 as a suitable substrate for easier deposition of AuNPs as well as rapid immobilization of aptamers on the surface of the electrode, which improved the electrochemical conductivity of the rGO sheets and the sensitivity of the fabricated biosensor. MiRNA-128 was then detected in low concentrations using label-free and methylene blue-labeled methods (Figure 2). Both label-free and labeled aptasensors showed high selectivity for miRNA-128. Their proposed platform could be integrated into wearable biosensors for real-time monitoring of individuals. Furthermore, compared to the previous studies, they could detect miRNA-128 at a very low concentration (fM), confirming the high applicability of the developed nano-biosensor for early detection of ALL.
Amouzadeh Tabrizi et al. [24] designed a flow injection aptamer–aptamer sandwich electrochemical biosensor for determination of CCRF-CEM cells in the presence of H2O2 as an electroactive component. They used a nanoplatform of poly (3,4-ethylenedioxythiophene) decorated with Au NPs for immobilizing the thiolated sgs8c aptamer and multiwall carbon nanotubes decorated with perylene tetracarboxylic acid and palladium NPs for catalytic labeling of aptamer. Then, the CCRF-CEM cells were sandwiched between them. The catalytically labeled aptamer bound to the CCRF-CEM cells catalyzes the electrocatalytic reduction of H2O2 and enhances the electrocatalytic reduction signal of H2O2 depending on the concentration of CCRF-CEM cells. With the proposed setup, they could also determine the CCRF-CEM cancer cells in human serum samples.
Recently, Rinaldi et al. [72] presented an electrochemical sandwich immunosensor as a point-of-care test for CCL17/TARC detection as a potential biomarker of cHL (Figure 3). The proposed sensor was able to distinguish patients with cHL from healthy volunteers as well as perform secondary care chemotherapy monitoring. In this regard, a gold electrode was first modified with a thiolated heterobifunctional crosslinker, Sulfo-LC-SPDP, to immobilize the specific capture antibody. Then, a biotinylated CCL17 secondary antibody conjugated with an enzyme was added to develop the final sandwich immunosensor for the determination of the CCL17/TARC level in the serum of a patient with cHL. The designed biosensor with lower and upper quantitation limits of 387 and 50,000 pg/mL towards CCL17/TARC showed a high dynamic range compared to the equivalent colorimetric ELISA platform, implying an essential step towards developing a rapid test for the staging and treatment of cHL.
A label-free electrochemical biosensor was designed based on Zr/metal-organic frameworks (Zr-MOFs) for early detection of GBM-derived exosomes in the blood of patients with GBM. These exosomes are marked by highly expressed human epidural growth factor receptor (EGFR) and EGFR variant (v) III mutations (EGFRvIII). Therefore, a peptide ligand was attached to the electrode surface as a sensing layer that could specifically bind to EGFR and EGFRvIII and capture GBM-derived exosomes. At the same time, encapsulated Zr-MOFs with methylene blue were combined with the GBM-derived exosomes through the interaction of phosphate groups of exosomes with Zr4+ and produced an electrochemical signal. The proposed method was able to quantitatively measure the concentration of GBM-derived exosomes, ranging from 9.5 × 103 to 1.9 × 107 particles/μL, with a detection limit of 7.83 × 103 particles/μL. In addition, the prepared biosensing platform was used to analyze GBM-derived exosomes in human serum. It could distinguish GBM patients from healthy groups, demonstrating its feasibility for early diagnosis and monitoring of GBM therapy [43].
Moazzam et al. [90] fabricated an ultrasensitive and fast electrochemical biosensor for direct detection of PD-L1 in whole-blood samples using a dispersible electrode based on modified gold-coated magnetic nanoparticles (Figure 4). First, a labeled antibody conjugated with gold-coated magnetic nanoparticles (Ab1-Au@MNPs) was added to the PD-L1 solution in the blood. Then, the resulting magnetically separated PD-L1-Ab1-Au@MNPs were mixed with a second reporter antibody (biotinylated detection antibody) conjugated with a horseradish-peroxidase–streptavidin-labeled (HRP-Ab2) to build an immunosandwich structure of HRP-Ab2-(PD-L1)-Ab1-Au@MNPs. Then, the separated sandwiched HRP-Ab2-(PD-L1)-Ab1-Au@MNPs were collected on the gold macroelectrode surface (as working electrode) by applying a magnet, and PD-L1 detection was performed in ferrocenemethanol (Fc) solution as a redox mediator and in the presence of H2O2 as a substrate of HRP. The reported dispersible electrochemical sensor was able to detect PD-L1 with an ultralow detection limit of 15 attomolar, which is 2600 000 times lower than the detection limit obtained with commercially available ELISA kits.

4.2. Optical Biosensors

Optical biosensing technology is the second class of biosensors, after electrochemical, that has been extensively studied in cancer diagnostics and therapy. It can detect cancer biomarkers easily, directly, and in real time. Optical biosensors generally include colorimetric, fluorometric, chemiluminescence, and surface plasmon resonance (SPR)-based biosensors.
To develop a non-invasive liquid biopsy for early diagnosis of leukemia with high sensitivity and specificity, Huang et al. [91] proposed a dual-signal amplification fluorescent protocol to detect leukemia-derived nanosized exosomes. As shown in Figure 5, they first modified magnetic bead conjugates with anti-CD63 antibodies (MB-CD63) to entrap leukemia-cell-derived exosomes containing CD63 and nucleolin. Subsequently, a DNA primer with a nucleolin recognition aptamer (AS1411) was used to bind to the exosome, triggering a rolling circle amplification (RCA) reaction, to generate multiple repeated sequences for hybridization of fluorescent-labeled DNA (DNA-FAM), which was immobilized on AuNPs (GNP-DNA-FAM). Here, the fluorescence of FAM is quenched by AuNPs due to its specific optical effect. In the last step, they introduced nicking endonuclease (Nb·BbvCI) assisted target recycling, resulting in the release of FAM from the GNP-DNA-FAM conjugates, which transitioned from the quenching state to the emission state so that the fluorescence signals gradually increased. Using the suggested platform as a dual signal amplification strategy, they could detect exosomes at concentrations as low as 100 particles per μL.
Luo et al. [92] prepared a localized surface plasmon resonance (LSPR) biosensing platform for the specific detection of serum PD-L1 using excessively tilted fiber grating (ExTFG) coated with large-sized (∼160 nm) gold nanoshells. Anti-PD-L1 monoclonal antibodies were immobilized on an ExTFG-LSPR platform for label-free detection of PD-L1. The designed biosensor was able to specifically detect PD-L1 at a low concentration of 5 pg/mL in fetal bovine serum as a complex serum medium.
Recently, an LSPR biosensor chip was developed based on the immobilization of antibodies on the surface of Au nano-islands decorated with AgNPs (Ag@AuNIs) for the detection of monocarboxylate transporter 4 (MCT4) as a GBM progression biomarker [93]. The anti-MCT4 antibodies on the surface of Ag@AuNIs-modified chips had a remarkable ability to detect exosomes, resulting in the generation of a strong LSPR response. Therefore, the proposed biosensor sensitively and selectively detected the enhancement of MCT4 content in malignant hypoxic GBM cell-derived exosomes and the increased MCT4 content in exosomes from blood serum of GBM mice in a wide dynamic range, with a detection limit of 0.4 ng/mL, confirming its potential for early detection of GBM initiation and progression.
PD-L1 expressing extracellular vehicles (EVs) are of remarkable clinical relevance, since they have the potential to diagnosis cancer and to evaluate the patient’s response to anti-PD-L1/PD-L1 immunotherapy. In this context, Khan et al. [94] developed an aptamer-based chemiluminescence (CL) sensor for the detection of PD-L1@EVs using Fe3O4@TiO2 beads to capture EVs directly from undiluted serum without the need for additional ultracentrifugation and isolation. To improve specificity, a biotin-labeled PD-L1 aptamer was first added to bind to PD-L1@EVs. Streptavidin-modified alkaline phosphates (ALP) were then added to bind the aptamer via the strong biotin–streptavidin binding. The addition of CDP-Star, a chemiluminescent ALP substrate, triggers chemiluminescence proportional to the concentration of PD-L1@EVs. The prepared assay showed high sensitivity and specificity towards PD-L1@EVs in a wide linear range of 105 to 108 EVs/mL and a very low detection limit of 2.584 × 105 EVs/mL.
Recently, electrochemiluminescence (ECL) (the combination of electrochemical methods and chemiluminescence) has gained popularity in sensor and biosensor applications due to the numerous advantages of ECL over chemiluminescence, such as controlled selectivity by changing the electrode potential, higher sensitivity, and time and position control of the light-emitting response. An ECL aptasensor for the detection of miRNA-16 in patients with leukemia based on polymerase-assisted signal amplification and aggregation of the illuminator was reported by Zhang et al. [95]. The assembled mercapto-modified capture DNA (CP) on Fe3O4@Au NPs was immobilized on the surface of a magneto-controlled glassy carbon electrode by Au-S bond, which was then hybridized with the target miRNA-16. In the presence of bases, primer, and polymerase, the polymerization began, leading to the release of miRNA-16. After the hybridization reaction between the probe DNA (PDNA) and the remaining sequence of the CP’s stem component and formation of the core–shell sun-like structure, they embedded pyridine ruthenium (Ru(bpy)32+) complex into the assistance DNA (ADNA), which was loaded on a nanogold surface. Lastly, the composite of AuNPs@(PDNA+ADNA- Ru(bpy)32+ was added and the ECL intensity was recorded. Due to the polymerization cycle and aggregation of Ru(bpy)32+ as the illuminator, they were able to significantly increase the sensitivity and detect miRNA 16 at a very low concentration, with a detection limit of 4.3 × 10−17 cells/mL.

4.3. Electrical Biosensors

Electrical biosensors provide label-free, rapid, highly sensitive and direct detection of biomolecules. In electrical biosensors, capturing a target by a biological receptor results in a change in potential, impedance, or current that can be correlated with target concentration. Recently, electrical biosensors based on semiconductor nanowires and nanoribbons have been considered for real-time and label-free detection of macromolecules and cancer biomarkers at subfemtomolar concentrations [96,97]. Silicon nanoribbons as extended silicon nanostructures have been recently introduced as highly sensitive (bio)sensor chips for potential use in medicine and biotechnology when at least femtomolar or lower detection is required [98,99,100]. Ivanov et al. [101] developed a silicon nanoribbon-based DNA-biosensor for the detection of circular RNA nuclear factor IX (circNFIX) as a molecular biomarker of glioma in humans (Figure 6). Using the proposed assay, they were able to detect circNFIX in plasma samples from glioma patients with a limit of detection of 1.1 × 10−17 M in real time. A summary of developed biosensors for childhood cancer is shown in Table 1.
A list of the abbreviations used in this review is provided in Table 2.

5. Conclusions and Future Outlook

This review highlights the concern about childhood cancers and the importance of biomarker detection for early diagnosis and prognosis of malignancies in this age group. Biosensors are shown to be an accurate, non-invasive, and rapid technology for detecting specific biomarkers of childhood cancers. However, biosensors should have high sensitivity to detect very low levels of biomarkers at the early stages of cancer. The application of nanotechnology in developing biosensors has had a tremendous impact on the sensitive detection of biomarkers at the trace level, allowing earlier diagnosis of cancer and improved patient survival. On the other hand, detecting a panel of biomarkers associated with a particular cancer type may reduce diagnostic time and ultimately positively impact clinical outcomes. In this context, the integration of nanomaterials into electrochemical biosensors makes them the best candidates for future clinical applications in simultaneous measurement of multiple biomarkers, because of their ease of use, their fast and highly sensitive response, and the possibility of miniaturization as well as the development of point-of-care devices. Considering the limited research on biosensors for childhood cancers, studies and development of ultrasensitive and wearable biosensors for clinical use have great potential, not only for non-invasive and cost-effective diagnosis of pediatric cancers, but also for monitoring the patient’s treatment progress. However, a comprehensive understanding of molecular changes, cancer cell behavior, and associated biomarkers, as well as the mechanisms of interaction between nanomaterials on the surface of biosensors and various biomarkers, are the major challenges in biosensor design and require further investigation.

Author Contributions

Y.J., P.R. and A.G. contributed to the conceptualization and implementation. The writing of the original draft was performed by A.G. The design, review, and editing were carried out by Y.J., S.F., M.Z. and P.R. All authors provided critical feedback and helped shape the research and manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. WHO. CureAll Framework: WHO Global Initiative for Childhood Cancer: Increasing Access, Advancing Quality, Saving Lives; WHO: Geneva, Switzerland, 2021. [Google Scholar]
  2. Zhang, J.; Walsh, M.F.; Wu, G.; Edmonson, M.N.; Gruber, T.A.; Easton, J.; Hedges, D.; Ma, X.; Zhou, X.; Yergeau, D.A. Germline mutations in predisposition genes in pediatric cancer. N. Engl. J. Med. 2015, 373, 2336–2346. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Lam, C.G.; Howard, S.C.; Bouffet, E.; Pritchard-Jones, K. Science and health for all children with cancer. Science 2019, 363, 1182–1186. [Google Scholar] [CrossRef] [PubMed]
  4. Magrath, I.; Steliarova-Foucher, E.; Epelman, S.; Ribeiro, R.C.; Harif, M.; Li, C.-K.; Kebudi, R.; Macfarlane, S.D.; Howard, S.C. Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 2013, 14, e104–e116. [Google Scholar] [CrossRef]
  5. Steliarova-Foucher, E.; Colombet, M.; Ries, L.A.G.; Moreno, F.; Dolya, A.; Bray, F.; Hesseling, P.; Shin, H.Y.; Stiller, C.A.; Bouzbid, S. International incidence of childhood cancer, 2001–2010: A population-based registry study. Lancet Oncol. 2017, 18, 719–731. [Google Scholar] [CrossRef]
  6. Frangioni, J.V. New technologies for human cancer imaging. J. Clin. Oncol. 2008, 26, 4012. [Google Scholar] [CrossRef] [PubMed]
  7. Schiffman, J.D.; Fisher, P.G.; Gibbs, P. Early detection of cancer: Past, present, and future. Am. Soc. Clin. Oncol. Educ. Book 2015, 35, 57–65. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Stachowicz-Stencel, T.; Synakiewicz, A. Biomarkers for pediatric cancer detection: Latest advances and future perspectives. Biomark. Med. 2020, 14, 391–400. [Google Scholar] [CrossRef]
  9. Golubnitschaja, O.; Flammer, J. What are the biomarkers for glaucoma? Surv. Ophthalmol. 2007, 52, S155–S161. [Google Scholar] [CrossRef]
  10. Sawyers, C.L. The cancer biomarker problem. Nature 2008, 452, 548–552. [Google Scholar] [CrossRef]
  11. An, Q.; Fan, C.H.; Xu, S.M. Recent perspectives of pediatric leukemia–an update. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 31–36. [Google Scholar]
  12. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 2021, 71, 7–33. [Google Scholar] [CrossRef] [PubMed]
  13. Hasanbegović, E. Modern approach to diagnosis and therapy in childhood leukemias. Med. Arh. 2004, 58, 59–60. [Google Scholar] [PubMed]
  14. Ward, E.; DeSantis, C.; Robbins, A.; Kohler, B.; Jemal, A. Childhood and adolescent cancer statistics, 2014. CA A Cancer J. Clin. 2014, 64, 83–103. [Google Scholar] [CrossRef]
  15. Kaplan, J.A. Leukemia in children. Pediatrics Rev. 2019, 40, 319–331. [Google Scholar] [CrossRef] [PubMed]
  16. Chiaretti, S.; Zini, G.; Bassan, R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr. J. Hematol. Infect. Dis. 2014, 6, e2014073. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Hrusak, O.; Mejstrikova, E.; Zdrahalova, K.; Kramarzova, K.; Kovac, M.; Trka, J.; Stary, J. Prognosis of ProB ALL in Children. Blood 2008, 112, 2512. [Google Scholar] [CrossRef]
  18. Pui, C.-H.; Relling, M.V.; Downing, J.R. Acute lymphoblastic leukemia. N. Engl. J. Med. 2004, 350, 1535–1548. [Google Scholar] [CrossRef] [Green Version]
  19. Saletta, F.; Wadham, C.; Ziegler, D.S.; Marshall, G.M.; Haber, M.; McCowage, G.; Norris, M.D.; Byrne, J.A. Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clin. 2014, 1, 59–77. [Google Scholar] [CrossRef] [Green Version]
  20. Shi, L.; Zhang, J.; Wu, P.; Feng, K.; Li, J.; Xie, Z.; Xue, P.; Cai, T.; Cui, Z.; Chen, X. Discovery and identification of potential biomarkers of pediatric acute lymphoblastic leukemia. Proteome Sci. 2009, 7, 1–12. [Google Scholar] [CrossRef] [Green Version]
  21. Ghodousi, E.S.; Rahgozar, S. MicroRNA-326 and microRNA-200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia. J. Cell. Biochem. 2018, 119, 6024–6032. [Google Scholar] [CrossRef]
  22. Zamani, A.; Dolatabadi, N.F.; Houshmand, M.; Nabavizadeh, N. miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia. Leuk. Res. 2021, 109, 106643. [Google Scholar] [CrossRef] [PubMed]
  23. Dinani, H.S.; Pourmadadi, M.; Yazdian, F.; Rashedi, H.; Ebrahimi, S.A.S.; Shayeh, J.S.; Ghorbani, M. Fabrication of Au/Fe3O4/RGO based aptasensor for measurement of miRNA-128, a biomarker for acute lymphoblastic leukemia (ALL). Eng. Life Sci. 2022, 22, 519–534. [Google Scholar] [CrossRef] [PubMed]
  24. Tabrizi, M.A.; Shamsipur, M.; Saber, R.; Sarkar, S. Flow injection amperometric sandwich-type aptasensor for the determination of human leukemic lymphoblast cancer cells using MWCNTs-Pdnano/PTCA/aptamer as labeled aptamer for the signal amplification. Anal. Chim. Acta 2017, 985, 61–68. [Google Scholar] [CrossRef] [PubMed]
  25. Fleming, A.J.; Chi, S.N. Brain Tumors in Children 80. Curr. Probl. Pediatr. Adolesc. Health Care 2012, 42, 80–103. [Google Scholar] [CrossRef]
  26. Wells, E.M.; Packer, R.J. Pediatric brain tumors. CONTINUUM Lifelong Learn. Neurol. 2015, 21, 373–396. [Google Scholar] [CrossRef] [PubMed]
  27. Wilne, S.H.; Ferris, R.C.; Nathwani, A.; Kennedy, C.R. The presenting features of brain tumours: A review of 200 cases. Arch. Dis. Child. 2006, 91, 502–506. [Google Scholar] [CrossRef]
  28. El-Jawahri, A.; Patel, D.; Zhang, M.; Mladkova, N.; Chakravarti, A. Biomarkers of Clinical Responsiveness in Brain Tumor Patients. Mol. Diagn. Ther. 2008, 12, 199–208. [Google Scholar] [CrossRef]
  29. Baig, M.A.; Klein, J.P.; Mechtler, L.L. Imaging of brain tumors. CONTINUUM Lifelong Learn. Neurol. 2016, 22, 1529–1552. [Google Scholar] [CrossRef]
  30. Lehner, K.R.; Jiang, K.; Rincon-Torroella, J.; Perera, R.; Bettegowda, C. Cerebrospinal Fluid biomarkers in pediatric brain tumors: A systematic review. Neoplasia 2023, 35, 100852. [Google Scholar] [CrossRef]
  31. Spreafico, F.; Bongarzone, I.; Pizzamiglio, S.; Magni, R.; Taverna, E.; de Bortoli, M.; Ciniselli, C.M.; Barzanò, E.; Biassoni, V.; Luchini, A. Proteomic analysis of cerebrospinal fluid from children with central nervous system tumors identifies candidate proteins relating to tumor metastatic spread. Oncotarget 2017, 8, 46177. [Google Scholar] [CrossRef] [Green Version]
  32. Bruschi, M.; Petretto, A.; Cama, A.; Pavanello, M.; Bartolucci, M.; Morana, G.; Ramenghi, L.A.; Garré, M.L.; Ghiggeri, G.M.; Panfoli, I. Potential biomarkers of childhood brain tumor identified by proteomics of cerebrospinal fluid from extraventricular drainage (EVD). Sci. Rep. 2021, 11, 1818. [Google Scholar] [CrossRef] [PubMed]
  33. Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016, 131, 803–820. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Shiraki, Y.; Mii, S.; Enomoto, A.; Momota, H.; Han, Y.-P.; Kato, T.; Ushida, K.; Kato, A.; Asai, N.; Murakumo, Y. Significance of perivascular tumour cells defined by CD109 expression in progression of glioma. J. Pathol. 2017, 243, 468–480. [Google Scholar] [CrossRef]
  35. Hashimoto, M.; Ichihara, M.; Watanabe, T.; Kawai, K.; Koshikawa, K.; Yuasa, N.; Takahashi, T.; Yatabe, Y.; Murakumo, Y.; Zhang, J. Expression of CD109 in human cancer. Oncogene 2004, 23, 3716–3720. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Xue, J.; Chen, Y.; Wu, Y.; Wang, Z.; Zhou, A.; Zhang, S.; Lin, K.; Aldape, K.; Majumder, S.; Lu, Z. Tumour suppressor TRIM33 targets nuclear β-catenin degradation. Nat. Commun. 2015, 6, 6156. [Google Scholar] [CrossRef] [Green Version]
  37. Collins, V.P.; Jones, D.T.W.; Giannini, C. Pilocytic astrocytoma: Pathology, molecular mechanisms and markers. Acta Neuropathol. 2015, 129, 775–788. [Google Scholar] [CrossRef] [Green Version]
  38. Bookland, M.; Tang-Schomer, M.; Gillan, E.; Kolmakova, A. Circulating serum oncologic miRNA in pediatric juvenile pilocytic astrocytoma patients predicts mural nodule volume. Acta Neurochir. 2018, 160, 1571–1581. [Google Scholar] [CrossRef]
  39. Alexiou, G.A.; Vartholomatos, G.; Stefanaki, K.; Patereli, A.; Dova, L.; Karamoutsios, A.; Lallas, G.; Sfakianos, G.; Moschovi, M.; Prodromou, N. Expression of heat shock proteins in medulloblastoma. J. Neurosurg. Pediatr. 2013, 12, 452–457. [Google Scholar] [CrossRef]
  40. Millard, N.E.; de Braganca, K.C. Medulloblastoma. J. Child Neurol. 2016, 31, 1341–1353. [Google Scholar] [CrossRef] [Green Version]
  41. Matta, A.; Siu, K.M.; Ralhan, R. 14-3-3 zeta as novel molecular target for cancer therapy. Expert Opin. Ther. Targets 2012, 16, 515–523. [Google Scholar] [CrossRef]
  42. Xu, H.; Zhang, Y.; Qi, L.; Ding, L.; Jiang, H.; Yu, H. NFIX circular RNA promotes glioma progression by regulating miR-34a-5p via notch signaling pathway. Front. Mol. Neurosci. 2018, 11, 225. [Google Scholar] [CrossRef] [PubMed]
  43. Sun, Z.; Wang, L.; Wu, S.; Pan, Y.; Dong, Y.; Zhu, S.; Yang, J.; Yin, Y.; Li, G. An electrochemical biosensor designed by using Zr-based metal–organic frameworks for the detection of glioblastoma-derived exosomes with practical application. Anal. Chem. 2020, 92, 3819–3826. [Google Scholar] [CrossRef] [PubMed]
  44. Irwin, M.S.; Park, J.R. Neuroblastoma: Paradigm for precision medicine. Pediatric Clin. 2015, 62, 225–256. [Google Scholar]
  45. Ross, I.L.; Louw, G.J. Embryological and molecular development of the adrenal glands. Clin. Anat. 2015, 28, 235–242. [Google Scholar] [CrossRef] [PubMed]
  46. Ahmed, A.A.; Zhang, L.; Reddivalla, N.; Hetherington, M. Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors. Pediatric Hematol. Oncol. 2017, 34, 165–185. [Google Scholar] [CrossRef]
  47. London, W.B.; Castleberry, R.P.; Matthay, K.K.; Look, A.T.; Seeger, R.C.; Shimada, H.; Thorner, P.; Brodeur, G.; Maris, J.M.; Reynolds, C.P. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J. Clin. Oncol. 2005, 23, 6459–6465. [Google Scholar] [CrossRef]
  48. Henderson, T.O.; Bhatia, S.; Pinto, N.; London, W.B.; McGrady, P.; Crotty, C.; Sun, C.-L.; Cohn, S.L. Racial and ethnic disparities in risk and survival in children with neuroblastoma: A Children’s Oncology Group study. J. Clin. Oncol. 2011, 29, 76. [Google Scholar] [CrossRef] [Green Version]
  49. Pollard, Z.F.; Greenberg, M.F.; Bordenca, M.; Lange, J. Atypical acquired pediatric Horner syndrome. Arch. Ophthalmol. 2010, 128, 937–940. [Google Scholar] [CrossRef] [Green Version]
  50. Dumba, M.; Jawad, N.; McHugh, K. Neuroblastoma and nephroblastoma: A radiological review. Cancer Imaging 2015, 15, 5. [Google Scholar] [CrossRef] [Green Version]
  51. Mueller, W.P.; Coppenrath, E.; Pfluger, T. Nuclear medicine and multimodality imaging of pediatric neuroblastoma. Pediatr. Radiol. 2013, 43, 418–427. [Google Scholar] [CrossRef]
  52. Shawraba, F.; Hammoud, H.; Mrad, Y.; Saker, Z.; Fares, Y.; Harati, H.; Bahmad, H.F.; Nabha, S. Biomarkers in Neuroblastoma: An Insight into Their Potential Diagnostic and Prognostic Utilities. Curr. Treat. Opt. Oncol. 2021, 22, 102. [Google Scholar] [CrossRef] [PubMed]
  53. Murray, M.J.; Raby, K.L.; Saini, H.K.; Bailey, S.; Wool, S.V.; Tunnacliffe, J.M.; Enright, A.J.; Nicholson, J.C.; Coleman, N. Solid Tumors of Childhood Display Specific Serum microRNA ProfilesSerum microRNAs in Childhood Tumors. Cancer Epidemiol. Biomark. Prev. 2015, 24, 350–360. [Google Scholar] [CrossRef] [PubMed]
  54. Zhuo, Z.; Lin, L.; Miao, L.; Li, M.; He, J. Advances in liquid biopsy in neuroblastoma. Fundam. Res. 2022, 2, 903–917. [Google Scholar] [CrossRef]
  55. Pastore, G.; Znaor, A.; Spreafico, F.; Graf, N.; Pritchard-Jones, K.; Steliarova-Foucher, E. Malignant renal tumours incidence and survival in European children (1978–1997): Report from the Automated Childhood Cancer Information System project. Eur. J. Cancer 2006, 42, 2103–2114. [Google Scholar] [CrossRef] [PubMed]
  56. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
  57. Martínez, C.H.; Dave, S.; Izawa, J. Wilms’ tumor. Dis. DNA Repair 2010, 685, 196–209. [Google Scholar]
  58. Lange, J.; Peterson, S.M.; Takashima, J.R.; Grigoriev, Y.; Ritchey, M.L.; Shamberger, R.C.; Beckwith, J.B.; Perlman, E.; Green, D.M.; Breslow, N.E. Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor. J. Urol. 2011, 186, 378–386. [Google Scholar] [CrossRef] [Green Version]
  59. Mullen, E.; Graf, N. Clinical Presentation; Renal Tumors of Childhood–Biology and Therapy; Kathy Pritchard-Jones and Jeff Dome; Springer: New York, NY, USA, 2014. [Google Scholar]
  60. Brok, J.; Treger, T.D.; Gooskens, S.L.; van den Heuvel-Eibrink, M.M.; Pritchard-Jones, K. Biology and treatment of renal tumours in childhood. Eur. J. Cancer 2016, 68, 179–195. [Google Scholar] [CrossRef] [Green Version]
  61. Pritchard-Jones, K.; Dome, J.S. Renal Tumors of Childhood; Springer: New York, NY, USA, 2014. [Google Scholar]
  62. Kaste, S.C.; Dome, J.S.; Babyn, P.S.; Graf, N.M.; Grundy, P.; Godzinski, J.; Levitt, G.A.; Jenkinson, H. Wilms tumour: Prognostic factors, staging, therapy and late effects. Pediatr. Radiol. 2008, 38, 2–17. [Google Scholar] [CrossRef]
  63. da Costa e Silva, E.J.; da Silva, G.A.P. Eliminating unenhanced CT when evaluating abdominal neoplasms in children. Am. J. Roentgenol. 2007, 189, 1211–1214. [Google Scholar] [CrossRef]
  64. Grundy, P.E.; Breslow, N.E.; Li, S.; Penman, E.; Beckwith, J.B.; Ritchey, M.L.; Shamberger, R.C.; Haase, G.M.; D’Angio, G.J.; Donaldson, M. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumor Study Group. J. Clin. Oncol. 2005, 23, 7312–7321. [Google Scholar] [CrossRef] [PubMed]
  65. Routh, J.C.; Grundy, P.E.; Anderson, J.R.; Retik, A.B.; Kurek, K.C. B7-h1 as a biomarker for therapy failure in patients with favorable histology Wilms tumor. J. Urol. 2013, 189, 1487–1492. [Google Scholar] [CrossRef] [PubMed]
  66. Sredni, S.T.; de Camargo, B.; Lopes, L.F.; Teixeira, R.; Simpson, A. Immunohistochemical detection of p53 protein expression as a prognostic indicator in Wilms tumor. Med. Pediatric Oncol. Off. J. SIOP—Int. Soc. Pediatric Oncol. Soc. Int. D’oncologie Pédiatrique 2001, 37, 455–458. [Google Scholar] [CrossRef] [PubMed]
  67. Ludwig, N.; Nourkami-Tutdibi, N.; Backes, C.; Lenhof, H.-P.; Graf, N.; Keller, A.; Meese, E. Circulating serum miRNAs as potential biomarkers for nephroblastoma. Pediatr. Blood Cancer 2015, 62, 1360–1367. [Google Scholar] [CrossRef] [PubMed]
  68. Nagpal, P.; Akl, M.R.; Ayoub, N.M.; Tomiyama, T.; Cousins, T.; Tai, B.; Carroll, N.; Nyrenda, T.; Bhattacharyya, P.; Harris, M.B. Pediatric Hodgkin lymphoma–biomarkers, drugs, and clinical trials for translational science and medicine. Oncotarget 2016, 7, 67551. [Google Scholar] [CrossRef] [Green Version]
  69. McCarten, K.M.; Nadel, H.R.; Shulkin, B.L.; Cho, S.Y. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. Pediatr. Radiol. 2019, 49, 1545–1564. [Google Scholar] [CrossRef]
  70. Johnson, S.A.; Kumar, A.; Matasar, M.J.; Schöder, H.; Rademaker, J. Imaging for staging and response assessment in lymphoma. Radiology 2015, 276, 323–338. [Google Scholar] [CrossRef] [Green Version]
  71. Jones, K.; Vari, F.; Keane, C.; Crooks, P.; Nourse, J.P.; Seymour, L.A.; Gottlieb, D.; Ritchie, D.; Gill, D.; Gandhi, M.K. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin. Cancer Res. 2013, 19, 731–742. [Google Scholar] [CrossRef] [Green Version]
  72. Rinaldi, C.; Corrigan, D.K.; Dennany, L.; Jarrett, R.F.; Lake, A.; Baker, M.J. Development of an Electrochemical CCL17/TARC Biosensor toward Rapid Triage and Monitoring of Classic Hodgkin Lymphoma. ACS Sens. 2021, 6, 3262–3272. [Google Scholar] [CrossRef]
  73. Farruggia, P.; Puccio, G.; Sala, A.; Todesco, A.; Buffardi, S.; Garaventa, A.; Bottigliero, G.; Bianchi, M.; Zecca, M.; Locatelli, F. The prognostic value of biological markers in paediatric Hodgkin lymphoma. Eur. J. Cancer 2016, 52, 33–40. [Google Scholar] [CrossRef]
  74. Yu, R.; Cheng, L.; Yang, S.; Liu, Y.; Zhu, Z. iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin’s Lymphoma. Front. Oncol. 2022, 12, 848286. [Google Scholar] [CrossRef]
  75. Arya, S.K.; Estrela, P. Recent advances in enhancement strategies for electrochemical ELISA-based immunoassays for cancer biomarker detection. Sensors 2018, 18, 2010. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Khan, A.H.; Sadroddiny, E. Application of immuno-PCR for the detection of early stage cancer. Mol. Cell. Probes 2016, 30, 106–112. [Google Scholar] [CrossRef]
  77. Mahmood, T.; Yang, P.-C. Western blot: Technique, theory, and trouble shooting. N. Am. J. Med. Sci. 2012, 4, 429. [Google Scholar] [PubMed]
  78. Orfao, A.; Ciudad, J.; Gonzalez, M.; Lopez, A.; Del Mar Abad, M.; Paz Bouza, J.I.; Cruz, J.J.; Alonso, A.G.; San Miguel, J.F. Flow cytometry in the diagnosis of cancer. Scand. J. Clin. Lab. Investig. 1995, 55, 145–152. [Google Scholar] [CrossRef]
  79. Zhao, L.-J.; Yu, R.-J.; Ma, W.; Han, H.-X.; Tian, H.; Qian, R.-C.; Long, Y.-T. Sensitive detection of protein biomarkers using silver nanoparticles enhanced immunofluorescence assay. Theranostics 2017, 7, 876. [Google Scholar] [CrossRef]
  80. Thevenot, D.R.; Toth, K.; Durst, R.A.; Wilson, G.S. Electrochemical biosensors: Recommended definitions and classification. Pure Appl. Chem. 1999, 71, 2333–2348. [Google Scholar] [CrossRef] [Green Version]
  81. Zourob, M.; Elwary, S.; Khademhosseini, A. Recognition Receptors in Biosensors; Springer: New York, NY, USA, 2010; ISBN 1441909192. [Google Scholar]
  82. Hamzah, A.A.; Nadzirah, S. Biosensors Development. In Encyclopedia of Sensors and Biosensors, 1st ed.; Narayan, R., Ed.; Elsevier: Amsterdam, The Netherlands, 2023; Volume 3, pp. 209–217. [Google Scholar]
  83. Naresh, V.; Lee, N. A review on biosensors and recent development of nanostructured materials-enabled biosensors. Sensors 2021, 21, 1109. [Google Scholar] [CrossRef] [PubMed]
  84. Sharifianjazi, F.; Rad, A.J.; Esmaeilkhanian, A.; Niazvand, F.; Bakhtiari, A.; Bazli, L.; Abniki, M.; Irani, M.; Moghanian, A. Biosensors and nanotechnology for cancer diagnosis (lung and bronchus, breast, prostate, and colon): A systematic review. Biomed. Mater. 2021, 17, 012002. [Google Scholar] [CrossRef]
  85. Li, X.; Ma, F.; Yang, M.; Zhang, J. Nanomaterial based analytical methods for breast cancer biomarker detection. Mater. Today Adv. 2022, 14, 100219. [Google Scholar] [CrossRef]
  86. Tothill, I.E. Biosensors for cancer markers diagnosis. Semin. Cell Dev. Biol. 2009, 20, 55–62. [Google Scholar] [CrossRef] [PubMed]
  87. Falahi, S.; Rafiee-Pour, H.-A.; Zarejousheghani, M.; Rahimi, P.; Joseph, Y. Non-coding RNA-based biosensors for early detection of liver cancer. Biomedicines 2021, 9, 964. [Google Scholar] [CrossRef] [PubMed]
  88. Mazloum-Ardakani, M.; Barazesh, B.; Moshtaghiun, S.M. A distinguished cancer-screening package containing a DNA sensor and an aptasensor for early and certain detection of acute lymphoblastic leukemia. Clin. Chim. Acta 2019, 497, 41–47. [Google Scholar] [CrossRef] [PubMed]
  89. Avelino, K.Y.; Frias, I.A.M.; Lucena-Silva, N.; Gomes, R.G.; de Melo, C.P.; Oliveira, M.D.L.; Andrade, C.A.S. Attomolar electrochemical detection of the BCR/ABL fusion gene based on an amplifying self-signal metal nanoparticle-conducting polymer hybrid composite. Colloids Surf. B Biointerfaces 2016, 148, 576–584. [Google Scholar] [CrossRef]
  90. RáGonšales, V.; JustináGooding, J. Ultrasensitive detection of programmed death-ligand 1 (PD-L1) in whole blood using dispersible electrodes. Chem. Commun. 2021, 57, 2559–2562. [Google Scholar]
  91. Huang, L.; Wang, D.-B.; Singh, N.; Yang, F.; Gu, N.; Zhang, X.-E. A dual-signal amplification platform for sensitive fluorescence biosensing of leukemia-derived exosomes. Nanoscale 2018, 10, 20289–20295. [Google Scholar] [CrossRef] [Green Version]
  92. Luo, B.; Wang, Y.; Lu, H.; Wu, S.; Lu, Y.; Shi, S.; Li, L.; Jiang, S.; Zhao, M. Label-free and specific detection of soluble programmed death ligand-1 using a localized surface plasmon resonance biosensor based on excessively tilted fiber gratings. Biomed. Opt. Express 2019, 10, 5136–5148. [Google Scholar] [CrossRef]
  93. Liu, L.; Thakur, A.; Li, W.K.; Qiu, G.; Yang, T.; He, B.; Lee, Y.; Wu, C.-M.L. Site specific biotinylated antibody functionalized Ag@ AuNIs LSPR biosensor for the ultrasensitive detection of exosomal MCT4, a glioblastoma progression biomarker. Chem. Eng. J. 2022, 446, 137383. [Google Scholar] [CrossRef]
  94. Khan, A.; Di, K.; Khan, H.; He, N.; Li, Z. Rapid Capturing and Chemiluminescent Sensing of Programmed Death Ligand-1 Expressing Extracellular Vesicles. Biosensors 2022, 12, 281. [Google Scholar] [CrossRef]
  95. Zhang, M.; Zhou, F.; Zhou, D.; Chen, D.; Hai, H.; Li, J. An aptamer biosensor for leukemia marker mRNA detection based on polymerase-assisted signal amplification and aggregation of illuminator. Anal. Bioanal. Chem. 2019, 411, 139–146. [Google Scholar] [CrossRef]
  96. Doucey, M.-A.; Carrara, S. Nanowire sensors in cancer. Trends Biotechnol. 2019, 37, 86–99. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  97. Ivanov, Y.D.; Pleshakova, T.O.; Malsagova, K.A.; Kozlov, A.F.; Kaysheva, A.L.; Shumov, I.D.; Galiullin, R.A.; Kurbatov, L.K.; Popov, V.P.; Naumova, O.V. Detection of marker miRNAs in plasma using SOI-NW biosensor. Sens. Actuators B Chem. 2018, 261, 566–571. [Google Scholar] [CrossRef]
  98. Elfström, N.; Karlström, A.E.; Linnros, J. Silicon nanoribbons for electrical detection of biomolecules. Nano Lett. 2008, 8, 945–949. [Google Scholar] [CrossRef] [PubMed]
  99. Malsagova, K.A.; Pleshakova, T.O.; Popov, V.P.; Kupriyanov, I.N.; Galiullin, R.A.; Kozlov, A.F.; Shumov, I.D.; Kaysheva, A.L.; Tikhonenko, F.V.; Archakov, A.I. Optical monitoring of the production quality of si-nanoribbon chips intended for the detection of ASD-associated oligonucleotides. Micromachines 2021, 12, 147. [Google Scholar] [CrossRef]
  100. Bao, Z.; Sun, J.; Zhao, X.; Li, Z.; Cui, S.; Meng, Q.; Zhang, Y.; Wang, T.; Jiang, Y. Top-down nanofabrication of silicon nanoribbon field effect transistor (Si-NR FET) for carcinoembryonic antigen detection. Int. J. Nanomed. 2017, 12, 4623. [Google Scholar] [CrossRef] [Green Version]
  101. Ivanov, Y.D.; Malsagova, K.A.; Popov, V.P.; Pleshakova, T.O.; Kozlov, A.F.; Galiullin, R.A.; Shumov, I.D.; Kapustina, S.I.; Tikhonenko, F.V.; Ziborov, V.S. Nanoribbon-based electronic detection of a glioma-associated circular miRNA. Biosensors 2021, 11, 237. [Google Scholar] [CrossRef]
Sensors 23 01482 g001 550
Figure 1. Schematic picture of a biosensor’s construction and function.
Figure 1. Schematic picture of a biosensor’s construction and function.
Sensors 23 01482 g001
Sensors 23 01482 g002 550
Figure 2. Schematic representation of Au NPs/Fe3O4/rGO nanocomposite preparation, immobilization of label-free as well as labeled aptamer on the surface of Au NPs/Fe3O4/rGO, and electrochemical analysis for determination of miRNA-128 concentration [23], reprinted with permission from WILEY.
Figure 2. Schematic representation of Au NPs/Fe3O4/rGO nanocomposite preparation, immobilization of label-free as well as labeled aptamer on the surface of Au NPs/Fe3O4/rGO, and electrochemical analysis for determination of miRNA-128 concentration [23], reprinted with permission from WILEY.
Sensors 23 01482 g002
Sensors 23 01482 g003 550
Figure 3. Schematic illustration of electrochemical immunosensor as a point-of-care test for detecting CCL17/TARC [72], reprinted with permission from American Chemical Society.
Figure 3. Schematic illustration of electrochemical immunosensor as a point-of-care test for detecting CCL17/TARC [72], reprinted with permission from American Chemical Society.
Sensors 23 01482 g003
Sensors 23 01482 g004 550
Figure 4. Schematic representation of working principle of the steps involved in the proposed sensing strategy for quantifying PD-L1 in undiluted whole-blood media [90], reprinted with permission from Royal Society of Chemistry.
Figure 4. Schematic representation of working principle of the steps involved in the proposed sensing strategy for quantifying PD-L1 in undiluted whole-blood media [90], reprinted with permission from Royal Society of Chemistry.
Sensors 23 01482 g004
Sensors 23 01482 g005 550
Figure 5. Schematic illustration of the dual-signal amplification-based platform for the ultrasensitive detection of exosomes. The primer contains the RCA primer (labeled in black) and AS1411 aptamer (labeled in gray) [91], reprinted with permission from Royal Society of Chemistry.
Figure 5. Schematic illustration of the dual-signal amplification-based platform for the ultrasensitive detection of exosomes. The primer contains the RCA primer (labeled in black) and AS1411 aptamer (labeled in gray) [91], reprinted with permission from Royal Society of Chemistry.
Sensors 23 01482 g005
Sensors 23 01482 g006 550
Figure 6. A schematic of the principle of the real-time nanoribbon (NR)-based RNA detection [101], reprinted with permission from MDPI.
Figure 6. A schematic of the principle of the real-time nanoribbon (NR)-based RNA detection [101], reprinted with permission from MDPI.
Sensors 23 01482 g006
Table
Table 1. Summary of developed biosensors for childhood cancers.
Table 1. Summary of developed biosensors for childhood cancers.
Biosensor MaterialDetection MethodBiomarkerRef.
DNA-aptamer/COD 1-Au NPsElectrochemicalBCR-ABL1/CEA[88]
NA/Au-NPs- PANI 2ElectrochemicalBCR-ABL[89]
Aptamer/Au NPs-Fe3O4-rGO 3ElectrochemicalmiRNA-128 [23]
Aptamer/PEDOT 4-Au NPsElectrochemicalCCRF-CEM cells[24]
Aptamer/Au NPs-Fe3O4-rGOElectrochemicalCCL17/TARC[72]
Protein/Zr-MOFs 5
Antibody/labeled
DNA/Au NPs
Antibody/ExTFG-Au 6
Antibody/Ag@AuNIs 7
Aptamer/Fe3O4@TiO2
Aptamer/Fe3O4@Au NPs
DNA/silicon		Electrochemical
Electrochemical
Optical
Optical
Optical
Optical
Optical
Electrical		GBM-derived exosome
PD-L1
leukemia-derived exosomes
PD-L1
MCT4 8
PD-L1
miRNA-16
circNFIX 9		[43]
[90]
[91]
[92]
[93]
[94]
[95]
[101]
1. COD: carbon quantum dots, 2. PANI: polyaniline, 3. rGO: reduced graphene oxide, 4. PEDOT: poly(3,4-ethylenedioxythiophene), 5. Zr-MOF: Zr/metal-organic frameworks, 6. excessively tilted fiber grating, 7. silver nanoparticles decorated on gold nano-islands, 8. MCT4: monocarboxylate transporter 4, 9. circNFIX: circular RNA nuclear factor IX.
Table
Table 2. List of abbreviations used in this review.
Table 2. List of abbreviations used in this review.
AbbreviationExplanationAbbreviationExplanation
LMICsLow- and middle-income
countries		AML1-ETOFusion protein resulting from t(8;21)(q22;q22) translocation
CNS Central nervous systemPML-RARAPromyelocytic leukemia/retinoic acid receptor alpha
CSFCerebrospinal fluidPF4Platelet factor 4
CTComputed tomographyCTAP IIIConnective tissue-activating peptide III
USUltrasoundC3aComplement component 3a
MRIMagnetic resonance imagingmiRNAMicro ribonucleic acid
USUltrasonographyCCRF-CEMHuman leukemic lymphoblast
SPECTSingle-photon emission computed tomographyMBMedulloblastoma
PETPositron emission tomographyTMSB4XTripartite motif-containing protein 33
DNADeoxyribonucleic acidHSPsHeat shock proteins
RNARibonucleic acidGBMGlioblastoma
WBCALLWhite blood cell
Acute lymphoblastic leukemia		ALKAnaplastic lymphoma receptor tyrosine kinase gene
AMLAcute lymphoblastic leukemiaMIBGMeta-iodobenzylguanidine
CMLChronic myeloid leukemiaNBNeuroblastoma
CDCluster of differentiationFDGFluorodeoxyglucose
TDTTerminal deoxyribonucleotidyl transferaseMYCNN-myc proto-oncogene protein
T-ALLThymic ALLPIM kinasePim-1 proto-oncogene, serine/threonine kinase
BCR-ABLChimeric gene of BCR and ABLTARCThymus and activation-regulated chemokine
TEL-AML1Fusion gene resulting from t(12;21) translocationCCL17/TARCC-C Motif Chemokine Ligand 17/thymus and activation-regulated chemokine
FUBP1Far-Upstream Element-Binding Protein 1cHLClassic Hodgkin lymphoma
UCHL1Ubiquitin C-Terminal Hydrolase L1NF-κBNuclear Factor Kappa B
TMODTropomodulin1S100A8S100 calcium-binding protein A8
NSENeuron-specific enolaseLRG1Leucine-rich alpha-2-glycoprotein 1
CTCsCirculating tumor cellsELISAEnzyme-linked immunosorbent assay
3-MT3-Methoxytyramine
HVAHomovanillic acidPCRPolymerase chain reaction
VMAVanillylmandelic acidCEACarcinoembryonic antigen
NMNNormetanephrineAu NPsGold nanoparticles
VLAVanillactic acidFe3O4Iron oxide
WTWilms tumor
WAGRWilms tumor, aniridia, genitourinary problems and range of developmental delaysrGOReduced graphene oxide
LOHLoss of heterozygosityH2O2Hydrogen peroxide
PD-L1Programmed death-ligand 1Sulfo-LC-SPDPSulfosuccinimidyl 6-[3′-(2- pyridyldithio)propionamido]hexanoate
HLHodgkin lymphomasZr-MOFsZr/metal-organic frameworks
NHLNon-Hodgkin lymphomasEGFREpidural growth factor receptor
Au@MNPs
Fc
SPR
LSPR
CL
ALS
ECL
circNFIX
NR 		Gold-coated magnetic nanoparticles
Ferrocenemethanol
Surface plasmon resonance
Localized surface plasmon resonance
Chemiluminescence
Alkaline phosphates
Electrochemiluminescence
Circular RNA nuclear factor IX
nanoribbon 		HRP
RCA
FAM
ExTFG
Au NIs
MCT4
EVs
TiO2
Ru(bpy)32+ 		Horseradish peroxidase
Rolling circle amplification
Fluorescent-label
Excessively tilted fiber grating
Au nano-islands
Monocarboxylate transporter 4
Extracellular vehicles
Titanium dioxide
Pyridine ruthenium complex
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Gharehzadehshirazi, A.; Zarejousheghani, M.; Falahi, S.; Joseph, Y.; Rahimi, P. Biomarkers and Corresponding Biosensors for Childhood Cancer Diagnostics. Sensors 2023, 23, 1482. https://doi.org/10.3390/s23031482

AMA Style

Gharehzadehshirazi A, Zarejousheghani M, Falahi S, Joseph Y, Rahimi P. Biomarkers and Corresponding Biosensors for Childhood Cancer Diagnostics. Sensors. 2023; 23(3):1482. https://doi.org/10.3390/s23031482

Chicago/Turabian Style

Gharehzadehshirazi, Azadeh, Mashaalah Zarejousheghani, Sedigheh Falahi, Yvonne Joseph, and Parvaneh Rahimi. 2023. "Biomarkers and Corresponding Biosensors for Childhood Cancer Diagnostics" Sensors 23, no. 3: 1482. https://doi.org/10.3390/s23031482

APA Style

Gharehzadehshirazi, A., Zarejousheghani, M., Falahi, S., Joseph, Y., & Rahimi, P. (2023). Biomarkers and Corresponding Biosensors for Childhood Cancer Diagnostics. Sensors, 23(3), 1482. https://doi.org/10.3390/s23031482

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop